AP2011005536A0 - Treatment of rheumatoid arthritis with mammal betadefensins. - Google Patents

Treatment of rheumatoid arthritis with mammal betadefensins.

Info

Publication number
AP2011005536A0
AP2011005536A0 AP2011005536A AP2011005536A AP2011005536A0 AP 2011005536 A0 AP2011005536 A0 AP 2011005536A0 AP 2011005536 A AP2011005536 A AP 2011005536A AP 2011005536 A AP2011005536 A AP 2011005536A AP 2011005536 A0 AP2011005536 A0 AP 2011005536A0
Authority
AP
ARIPO
Prior art keywords
betadefensins
mammal
treatment
rheumatoid arthritis
rheumatoid
Prior art date
Application number
AP2011005536A
Other languages
English (en)
Inventor
Karoline Sidelmann Brinch
Soeren Kjaerulff
Tanja Maria Rosenkilde Kjaer
Original Assignee
Novozymes Adenium Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes Adenium Biotech As filed Critical Novozymes Adenium Biotech As
Publication of AP2011005536A0 publication Critical patent/AP2011005536A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AP2011005536A 2008-07-18 2009-07-17 Treatment of rheumatoid arthritis with mammal betadefensins. AP2011005536A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08160761 2008-07-18
EP09160448 2009-05-15
PCT/EP2009/059255 WO2010007168A2 (en) 2008-07-18 2009-07-17 Treatment of rheumatoid arthritis with mammal beta defensins

Publications (1)

Publication Number Publication Date
AP2011005536A0 true AP2011005536A0 (en) 2011-02-28

Family

ID=41530821

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005536A AP2011005536A0 (en) 2008-07-18 2009-07-17 Treatment of rheumatoid arthritis with mammal betadefensins.

Country Status (17)

Country Link
US (2) US8232248B2 (ja)
EP (1) EP2320928B1 (ja)
JP (1) JP2011528334A (ja)
KR (1) KR20110031970A (ja)
CN (1) CN102159234A (ja)
AP (1) AP2011005536A0 (ja)
AR (1) AR072525A1 (ja)
AU (1) AU2009272683A1 (ja)
BR (1) BRPI0915778A2 (ja)
CA (1) CA2730666A1 (ja)
EA (1) EA201170220A1 (ja)
IL (1) IL210716A0 (ja)
MX (1) MX2011000567A (ja)
NZ (1) NZ590469A (ja)
TW (1) TW201004639A (ja)
WO (1) WO2010007168A2 (ja)
ZA (1) ZA201100460B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010007166A2 (en) 2008-07-18 2010-01-21 Novozymes A/S Treatment of inflammatory bowel diseases with mammal beta defensins
JP2011528332A (ja) * 2008-07-18 2011-11-17 ノボザイムス アデニウム バイオテック アクティーゼルスカブ 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置
KR101257228B1 (ko) * 2010-06-16 2013-04-29 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
NZ732118A (en) 2011-04-15 2018-11-30 Marine Polymer Tech Inc Treatment of disease with poly-n-acetylglucosamine nanofibers
ES2637286T3 (es) 2011-07-08 2017-10-11 Defensin Therapeutics Aps Tratamiento oral de la enfermedad inflamatoria intestinal
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide
KR102631542B1 (ko) * 2018-03-14 2024-02-01 서울대학교산학협력단 염증 감소능 및 줄기세포로부터 연골세포로의 분화 촉진능을 가지는 이중 기능성 펩타이드 및 이의 용도
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2004056307A2 (en) * 2002-12-19 2004-07-08 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
GB0514482D0 (en) 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
US8895062B2 (en) 2006-01-24 2014-11-25 University Of Maryland, Baltimore Surface-layer protein coated microspheres and uses thereof
JP5491396B2 (ja) 2007-09-11 2014-05-14 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのデフェンシンペプチドの使用
WO2010007166A2 (en) 2008-07-18 2010-01-21 Novozymes A/S Treatment of inflammatory bowel diseases with mammal beta defensins
JP2011528332A (ja) * 2008-07-18 2011-11-17 ノボザイムス アデニウム バイオテック アクティーゼルスカブ 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置

Also Published As

Publication number Publication date
US20120309686A1 (en) 2012-12-06
US8232248B2 (en) 2012-07-31
US20100016231A1 (en) 2010-01-21
JP2011528334A (ja) 2011-11-17
AR072525A1 (es) 2010-09-01
WO2010007168A3 (en) 2010-06-17
EA201170220A1 (ru) 2011-08-30
EP2320928B1 (en) 2012-11-07
EP2320928A2 (en) 2011-05-18
ZA201100460B (en) 2012-09-26
WO2010007168A2 (en) 2010-01-21
NZ590469A (en) 2012-08-31
KR20110031970A (ko) 2011-03-29
BRPI0915778A2 (pt) 2019-09-24
CN102159234A (zh) 2011-08-17
CA2730666A1 (en) 2010-01-21
MX2011000567A (es) 2011-02-23
TW201004639A (en) 2010-02-01
AU2009272683A1 (en) 2010-01-21
IL210716A0 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
PL2293816T3 (pl) Sposoby leczenia reumatoidalnego zapalenia stawów
GB201014633D0 (en) Rheumatoid arthritis treatment
GB0921731D0 (en) Theraputic uses
AP2012006167A0 (en) DLL4-binding molecules.
GB201117171D0 (en) Cuvette
AP2011005631A0 (en) Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment.
ZA201001584B (en) Quenching vessel
AP2011005536A0 (en) Treatment of rheumatoid arthritis with mammal betadefensins.
GB0918016D0 (en) Biosensor
GB0820412D0 (en) Pipelay vessel
EP2490007A4 (en) BOWL
EP2314678A4 (en) MICRO-RNA ASSOCIATED WITH RHEUMATOID ARTHRITIS
EP2439532A4 (en) BIOSENSOR
GB0810204D0 (en) Vessel
GB0914823D0 (en) The feedifier
WO2012018776A9 (en) Treating rheumatoid arthritis with anti-il-19 antibody
GB0920283D0 (en) The doggybreathe
EP2488875A4 (en) EVALUATION OF RHEUMATOID ARTHRITIS
GB0920369D0 (en) The cupster
SI2293816T1 (sl) Postopki za zdravljenje revmatoidnega artritisa
GB0922031D0 (en) Combination lock with two or more actions
HU0900007V0 (en) Cheque
GB2474580B (en) An improved bath
GB0903256D0 (en) L.E.D. level
GB0809319D0 (en) The treatment of puritus